5fluorouracil for Advanced Photoaging

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2011 by Federal University of São Paulo.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Federal University of São Paulo
ClinicalTrials.gov Identifier:
NCT01405144
First received: July 5, 2011
Last updated: July 28, 2011
Last verified: May 2011

July 5, 2011
July 28, 2011
August 2010
September 2011   (final data collection date for primary outcome measure)
  • Change in Photographic Evaluation [ Time Frame: 0, 60, 180 days ] [ Designated as safety issue: No ]
    Photographic blinded evaluation by two independent observers, comparing modifications of forearms skin overall aspect before and after 60 and 180 days of the treatments. The following 5 point scale will be used: -2=much worse; -1=worse; 0=inlatered; 1=better, 2= much better
  • Change in Microscopic Evaluation [ Time Frame: 0, 180 days ] [ Designated as safety issue: No ]
    Skin biopsies will be performed and coloration by hematoxilin-eosin, Verhoeff, Tricromio Masson , Picrosirius and biomarkers (p53, bcl2, collagen 1)will be used. The modifications on corneal layer and epidermal thickness, dermal elastotic material and collagen deposition and biomarkers expression will be evaluated by digital quantitative analysis, comparing the findings before (day 0) and after (day 180)treatments.
Same as current
Complete list of historical versions of study NCT01405144 on ClinicalTrials.gov Archive Site
  • Inflammatory Skin Reaction [ Time Frame: 30 day ] [ Designated as safety issue: Yes ]
    Comparison between treatments on inflammatory skin reaction will be performed by expression of interleucin-1, using immunohistochemistry
  • Occurence and Evaluation of Adverse Events [ Time Frame: 30, 60, 180 days ] [ Designated as safety issue: Yes ]
    Predictable and unpredictable side effects and their intensity related by patient and/or observed by investigator will be analized and compared between the treatments
  • Change in Patient Opinion [ Time Frame: 0, 30, 60, 180 days ] [ Designated as safety issue: No ]
    Patient opinion concerning modification on forearms skin overall aspect, using a 5 point scale: -2=much worse; -1=worse; 0=inaltered; 1=better, 2= much better, comparing day 0 to 60, 60 to 180 and 0 to 180.
  • Change in Investigator Clinical Evaluation [ Time Frame: 0, 30, 60, 180 days ] [ Designated as safety issue: No ]
    Investigator efficacy evaluation through actinic keratosis counting, on days 0, 30, 60 and 180 as weel as modification on forearms skin overall aspect. That will be performed by comparision of skin examination on days 60 and 180 to photography captured on days 0 and 60, i.e, 0 to 60, 60 to 180 and 0 to 180, using a 5 point scale: -2=much worse; -1=worse; 0=inaltered; 1=better, 2= much better
  • Change in Forearm Photoaging Classification [ Time Frame: 0, 60, 180 days ] [ Designated as safety issue: No ]
    A classification will be created and validated by investigators and five independent observers previously to classify forearm photoaging. After validation it will be applied to study subjects on days 0, 60 and 180 to evaluate modification on the forearm photoaging grade for each tretament.
Same as current
Not Provided
Not Provided
 
5fluorouracil for Advanced Photoaging
Phase III Comparative Study About the Use of 5% 5-fluorouracil Cream Versus Its Utilization as Agent for Sequential Superficial Peeling in the Treatment of Advanced Photoaging

It is well known the efficacy of 5% 5-fluoruracil for multiple and superficial actinic keratosis (AKs)treatment. Recently its additional benefit for advanced and severe photoaging while treating Aks was reported.

The aim of this study is to compare the efficacy and safety of the two modalities of 5% 5-FU use for forearms photoaging.

The use of 5% 5-fluorouracil (5-FU) cream, twice a day, during 3 weeks represents a classic treatment for multiple and superficial AKs. The main adverse event is the severe skin irritation leading to interruption of the treatment in some cases. In the last decade a superficial pulse-peeling using it as agent in sequential applications was described. This modality of treatment has been demonstrated efficacy and better tolerability.

The improvement of the overall aspect of photodamaged skin is observed while treating multiple AKs.

There are no comparative study between the two types of 5% 5-FU use. So that is the purpose of our clinical trial.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
  • Photoaging
  • Actinic Keratosis
  • Drug: 5-fluoruracil
    5% 5-fluoruracil cream, twice a day, during 3 weeks
    Other Name: Topical treatment
  • Procedure: 5-fluoruracil
    The same 30 patients will be submitted to 4 weekly application of superficial peeling using 5% 5-fluoruracil in propyleneglycol as vehicle. The applications will be performed by physician (one of the co-investigators)
    Other Name: Cosmetic procedure
  • Active Comparator: 5% 5-fluoruracil cream
    30 patients will use 5% 5-fluoruracil cream, twice a day, during 3 weeks, in one randomized forearm
    Intervention: Drug: 5-fluoruracil
  • Active Comparator: 5% 5-fluoruracil peeling
    The same 30 patients will be submitted to 4 applications of 5% 5-fluoruracil superficial peeling in the other forearm
    Intervention: Procedure: 5-fluoruracil
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
March 2012
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Healthy Men and women, aged from 50 to 75 anos;
  2. Phototype I a III (Fitzpatrick Classification);
  3. Advanced photoaging on forearms, with multiple superficial actinic keratosis;
  4. Agreement with no sun exposure during the study and
  5. Agreement with study conditions,capacity to understand and follow the orientations and form consent signature.

Exclusion Criteria:

  1. Topical treatment with:

    • tretinoin in the last 6 months ;
    • other retinoids, alpha-hydroxyacids, poli-hydroxyacids, beta-hydroxyacids and ascorbic acid in the last 3 months;
  2. Treatment by chemical peeling, microdermabrasion and non-ablative laser in the last 3 months;
  3. Treatment with systemic retinoid in the last 6 months ;
  4. Chemotherapy in the last 3 months;
  5. Hypersensibility to parabens;
  6. Infectious or inflammatory dermatosis on forearms;
  7. Clinical evidence of immunosuppression and
  8. Presence of photodermatosis
Both
50 Years to 75 Years
Yes
Contact: Edileia Bagatin, phD 55-11-94448848 edileia_bagatin@yahoo.com.br
Brazil
 
NCT01405144
Carol2011
Yes
Edileia Bagatin, Universidade Federal de Sao Paulo - Dermatology Department
Federal University of São Paulo
Not Provided
Study Chair: Ediléia Bagatin, PhD Professor
Federal University of São Paulo
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP